[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR010700A1 - Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene - Google Patents

Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene

Info

Publication number
AR010700A1
AR010700A1 ARP970105996A ARP970105996A AR010700A1 AR 010700 A1 AR010700 A1 AR 010700A1 AR P970105996 A ARP970105996 A AR P970105996A AR P970105996 A ARP970105996 A AR P970105996A AR 010700 A1 AR010700 A1 AR 010700A1
Authority
AR
Argentina
Prior art keywords
preparation
procedure
employment
substituted purine
agent containing
Prior art date
Application number
ARP970105996A
Other languages
English (en)
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of AR010700A1 publication Critical patent/AR010700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Derivados de purina sustituida, procedimiento para su preparacion, su empleo y su agente que los contiene. Son compuestos de formulas (I) y (Ia) endonde X, Y, W, Wa, G, y Ga tienen significados dados en las reivincicaciones, así como sussale s fisiologicamente tolerables y sus prodrogas, su preparacion,su empleo, especialmente como medicamento, y sus preparados farmacéuticos que los contienen. Los compuestos de la formula (I) son antagonistas de receptor devitronectina y puedenpor eje mplo introducirse como inhibidores de resorcion osea y para el tratamiento de la osteosporosis.
ARP970105996A 1996-12-20 1997-12-18 Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene AR010700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (1)

Publication Number Publication Date
AR010700A1 true AR010700A1 (es) 2000-06-28

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105996A AR010700A1 (es) 1996-12-20 1997-12-18 Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene

Country Status (22)

Country Link
EP (1) EP0853084B1 (es)
JP (1) JP4620190B2 (es)
KR (1) KR19980064655A (es)
CN (2) CN1101816C (es)
AR (1) AR010700A1 (es)
AT (1) ATE404562T1 (es)
AU (1) AU728865B2 (es)
BR (1) BR9706387A (es)
CA (1) CA2225366C (es)
CZ (1) CZ294437B6 (es)
DE (2) DE19653646A1 (es)
HK (1) HK1012190A1 (es)
HU (1) HUP9702507A3 (es)
ID (1) ID19254A (es)
IL (1) IL122642A0 (es)
NO (1) NO314583B1 (es)
NZ (1) NZ329431A (es)
PL (1) PL323969A1 (es)
RU (1) RU2228335C2 (es)
TR (1) TR199701647A3 (es)
TW (1) TW523515B (es)
ZA (1) ZA9711317B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042587A (ko) 1998-04-09 2001-05-25 기따자또 이찌로 인테그린 알파브이베타3 길항제로서 아미노피페리딘 유도체
EA006294B1 (ru) 1998-12-23 2005-10-27 Дж.Д.Сирл Энд Ко. Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
EP1176145A1 (en) 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EA201200560A1 (ru) 2006-01-18 2012-09-28 Мерк Патент Гмбх Специфическая терапия, использующая интегриновые лиганды для лечения рака
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
US8546540B2 (en) 2007-10-11 2013-10-01 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15
CN101909440A (zh) * 2007-11-14 2010-12-08 瑞科西有限公司 治疗用化合物及其在治疗疾病和障碍中的用途
EP3699277A1 (en) 2009-04-09 2020-08-26 Daiichi Sankyo Company, Limited Anti-siglec-15 antibody
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
EP2625205A2 (en) 2010-10-05 2013-08-14 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
MX2014011828A (es) 2012-03-30 2014-12-10 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 con region determinante de complementariedad modificada.
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (es) * 1966-12-10 1972-09-13
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
AU4729796A (en) * 1994-12-28 1996-07-19 Peter E. Nielsen Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
EP0840741B1 (en) * 1995-06-07 2004-04-28 Perseptive Biosystems, Inc. Pna-dna chimeras and pna synthons for their preparation
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
WO1997035846A1 (en) * 1996-03-26 1997-10-02 Dupont Pharmaceuticals Company Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
AU717387B2 (en) * 1996-07-24 2000-03-23 Rolf H. Berg Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
CN1101816C (zh) 2003-02-19
ZA9711317B (en) 1998-06-22
NO975977L (no) 1998-06-22
EP0853084B1 (de) 2008-08-13
HUP9702507A3 (en) 1999-12-28
TR199701647A2 (xx) 1998-07-21
JPH10182645A (ja) 1998-07-07
ID19254A (id) 1998-06-28
CZ294437B6 (cs) 2005-01-12
KR19980064655A (ko) 1998-10-07
NO314583B1 (no) 2003-04-14
EP0853084A3 (de) 1998-09-09
CA2225366A1 (en) 1998-06-20
HU9702507D0 (en) 1998-03-02
JP4620190B2 (ja) 2011-01-26
TR199701647A3 (tr) 1998-07-21
CN1495184A (zh) 2004-05-12
NO975977D0 (no) 1997-12-19
MX9710277A (es) 1998-10-31
PL323969A1 (en) 1998-06-22
EP0853084A2 (de) 1998-07-15
DE59712958D1 (de) 2008-09-25
HK1012190A1 (en) 1999-07-30
NZ329431A (en) 2000-01-28
DE19653646A1 (de) 1998-06-25
IL122642A0 (en) 1998-08-16
AU4846697A (en) 1998-06-25
HUP9702507A2 (hu) 1999-05-28
TW523515B (en) 2003-03-11
CA2225366C (en) 2006-10-10
RU2228335C2 (ru) 2004-05-10
ATE404562T1 (de) 2008-08-15
BR9706387A (pt) 2000-03-14
AU728865B2 (en) 2001-01-18
CZ411497A3 (cs) 1998-07-15
CN1193623A (zh) 1998-09-23

Similar Documents

Publication Publication Date Title
AR010700A1 (es) Derivados de purina sustituidos, procedimiento para su preparacion, su empleo y su agente que los contiene
UY27982A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
AR003220A1 (es) Derivados acilados de melatonina; composicion farmaceutica y cosmetica y el uso de los mismos para la preparacion de un medicamento.
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
AR025960A1 (es) Biblioteca de sustancias que contiene imidazo-5-il-aminas biciclicas y/o imidazo 3-il-aminas biciclicas, procedimiento para la preparacion de estabiblioteca de sustancias, y uso de sustancias de esta biblioteca para la preparacion de medicamentos para el tratamiento del dolor
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
CY1110600T1 (el) Αναλογα της βιταμινης d
AR029463A1 (es) Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
ECSP055685A (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
ECSP055679A (es) Derivados de pirazol como inhibidores del factor del crecimiento transformante (tgf)
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
YU47116B (sh) Postupak za dobijanje novih n-supstituisanih benzimidazolskih derivata
TR200401603T4 (tr) D vitamini benzerleri
ES2111556T3 (es) Nuevas aminas alquil-heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
MX9400070A (es) Compuestos heterociclicos, un procedimiento para prepararlos, su uso y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure